GS-6620

GS-6620 is an antiviral drug that was developed by Gilead Sciences for the treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. It is a nucleotide analogue inhibitor of the viral RNA polymerase, a key enzyme involved in the replication of the virus.

Mechanism of Action[edit | edit source]

GS-6620 works by inhibiting the RNA polymerase enzyme of the hepatitis C and B viruses. This enzyme is essential for the replication of the virus. By inhibiting this enzyme, GS-6620 prevents the virus from replicating and spreading to new cells.

Clinical Trials[edit | edit source]

GS-6620 has undergone several clinical trials to evaluate its safety and efficacy in treating HCV and HBV infections. In a phase 2 trial, GS-6620 demonstrated potent antiviral activity against HCV. However, further development of the drug was discontinued due to the emergence of more effective treatments for HCV.

Side Effects[edit | edit source]

Like all drugs, GS-6620 can cause side effects. The most common side effects reported in clinical trials include fatigue, headache, and nausea. Serious side effects are rare but can include liver damage and severe allergic reactions.